No Bad Faith To Justify Fee Award In Docs Suit, Biogen Says law360.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from law360.com Daily Mail and Mail on Sunday newspapers.
As a Delaware vice chancellor is set to consider a proposed stockholder suit settlement that will require five directors of life sciences venture CytoDyn Inc. to forfeit certain awards, three firms have come under fire for seeking $4.1 million in fees for their work on the case.
As a Delaware vice chancellor is set to consider a proposed stockholder suit settlement that will require five directors of life sciences venture CytoDyn Inc. to forfeit certain awards, three firms have come under fire for seeking $4.1 million in fees for their work on the case.
Zayo CEO Packed Board Ahead Of $14B Deal, Chancery Told law360.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from law360.com Daily Mail and Mail on Sunday newspapers.
Gross v. Biogen Inc
., C.A. No. 2020-0096-PAF (Del. Ch. Apr. 14, 2021).
On October 11, 2016, plaintiff Melvin Gross, served the first of four books-and-records demands on defendant Biogen Inc., under DGCL Section 220. Mr. Gross was a stockholder of Biogen at the time he made the demand. The demand sought eight categories of materials in order to: (1) “investigate possible corporate wrongdoing” and mismanagement related to state and federal investigations; and (2) “determine the independence of the Board members.” Biogen rejected the October 2016 demand, contending that it did not meet Section 220’s form and manner requirements, and that Gross lacked a proper purpose to inspect Biogen’s records. Through subsequent books-and-records demands on November 4, 2016, June 21, 2018, and December 3, 2019, Gross attempted to cure the alleged deficiencies, but succeeded only in prompting Biogen to argue that certain of the records sought were neither necessary nor essential to prop